Stock NERV MINERVA NEUROSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
2.51 USD +0.80% Intraday chart for Minerva Neurosciences, Inc. +4.58% -59.19%
05-01 Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-27 Sector Update: Health Care Stocks Ease Late Afternoon MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia.
MT
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback
DJ
FDA Turns Away Minerva's Roluperidone Schizophrenia Drug
DJ
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Minerva Neurosciences Says US FDA Accepts Filing of New Drug Application for Roluperidone to Treat Schizophrenia Symptoms
MT
Minerva Neurosciences, Inc. Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Minerva Neurosciences, Inc. Announces Update on its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Minerva Neurosciences Says FDA Doesn't Accept New Drug Application for Roluperidone; Shares Plunge Pre-Bell
MT
Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
CI
Minerva Neurosciences Shares Jump After Cohen's Point72 Reveals 8.8% Stake
MT
Minerva Neurosciences Files NDA to FDA for Roluperidone to Treat Schizophrenia Symptoms; Shares Surge
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NERV Stock
  4. News Minerva Neurosciences, Inc.
  5. Highlights